SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

March 6, 2023

https://www.globenewswire.com/news-release/2023/03/06/2621007/0/en/SciSparc-Successfully-Completed-Production-of-its-Proprietary-Drug-Candidate-SCI-110-for-its-Upcoming-Clinical-Trial-On-Tourette-Syndrome.html

TEL AVIV, Israel, March 06, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq:SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully manufactured clinical batches of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb trial for Tourette Syndrome (“TS”). 

Read more at globenewswire.com

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.